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Abstract
Malignant transformation in tumors is a complex process requiring accumula-
tion of numerous oncogenic abnormalities. Brain tumors show considerable 
phenotypic and genetic heterogeneity. In a series comprising diffuse infiltrating 
astrocytomas (DIA) and reactive gliosis, we investigated the main factors associ-
ated with signaling pathways. We assessed expression levels and their association 
with tumor progression and survival. We studied 19 grade II astrocytomas, 25 
anaplastic astrocytomas (grade III), 60 glioblastomas (grade IV), and 15 cases 
of reactive gliosis. Epidermal growth factor receptor (EGFR), pMAPK, 4E- BP1, 
p4E- BP1, pS6, eIF4E, and peIF4E expression levels were evaluated using im-
munohistochemistry. Expression levels were semiquantitatively evaluated using 
a histoscore. Immunohistochemistry and PCR were used for IDH1 mutations. 
Statistical analysis was based on the following tests: chi- square, Student’s t, 
Pearson correlation, Spearman’s rho, and Mann–Whitney; ROC and Kaplan–
Meier curves were constructed. A significant increase was observed between 
grades for expression of total and phosphorylated 4E- BP1 and for eIF4E, Ki67, 
EGFR, and cyclin D1. Although expression of EGFR, eIF4E, and Ki67 correlated 
with survival, only peIF4E was an independent predictor of survival in the 
multivariate analysis. Combining the evaluation of different proteins enables us 
to generate helpful diagnostic nomograms. In conclusion, cell signaling pathways 
are activated in DIAs; peIF4E is an independent prognostic factor and a promis-
ing therapeutic target. Joint analysis of the expression of 4E- BP1 and peIF4E 
could be helpful in the diagnosis of glioblastoma multiforme in small biopsy 
samples.
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Introduction
Diffuse infiltrating astrocytomas (DIA) are the most 
common primary brain tumors. The 2007 World Health 
Organization Classification [1] recognizes three grades 
of malignancy in these tumors, namely, diffuse astro-
cytoma (grade II), anaplastic astrocytoma (grade III), 
and glioblastoma multiforme (GBM, grade IV). Primary 
GBM appears de novo, with no previous history of 
brain tumor. Secondary GBM arises from a lower grade 
DIA and accounts for 5% of all GBMs. In addition, it 
is found in younger patients, in whom survival is longer. 
In molecular terms, amplification of epidermal growth 
factor receptor (EGFR) is the most distinctive marker 
of primary GBM, and mutations in IDH, TP53, and 
ATRX are the most distinctive markers of secondary 
GBM [2]. Despite advances in our knowledge of molecu-
lar abnormalities in these types of tumor, targets for 
efficacious treatment have not yet been identified in 
DIA.
The main cell signaling pathways—Ras- Raf- MAPK and 
PI3K- AKT- mTOR—are activated in many types of malig-
nant tumor [3–8]. The Ras- Raf- MAPK pathway phos-
phorylates eukaryotic translation initiation factor 4E 
(eIF4E) through the kinases MNK1 and MNK2. Activation 
of the PI3K- AKT- mTOR pathway phosphorylates the 
protein 4E- BP1 at its six phosphorylation sites. Other 
kinases such as CDK1 have also been associated with 
these pathways. Nonphosphorylated 4E- BP1 binds to 
eIF4E, thus blocking initiation of protein translation. 
When 4E- BP1 is phosphorylated, eIF4E is released and—
together with eIF4A and eIF4G—can form the eIF4F 
complex, which binds the mRNA strand and triggers 
translation. eIF4E is a key component in the initiation 
and regulation of translation to eukaryotic cells [4]: via 
its interaction with the 5′ cap structure of messenger 
RNA, eIF4E binds the mRNA strand to the ribosome. 
This is the least abundant initiation factor in terms of 
number of molecules per cell, thus giving it a key role 
in the regulation of translation. It has a single phospho-
rylation site, via which it interacts with eIF4G and 4E- 
BP1. eIF4G is a major anchor in the recruitment of the 
ribosome to mRNA, which in addition to eIF4E interacts 
with other components of translational machinery, such 
as eIF4A.
Both 4E- BP1 and eIF4E play a role in the progression 
and prognosis of various types of tumor [3, 5–9]. Several 
clinical trials have been performed, and new drugs tar-
geting these convergent factors are currently under study. 
The objective of the present study was to investigate 
the main proteins in both signaling pathways in order 
to identify possible prognostic and treatment factors in 
DIAs.
Patients and Methods
Patient selection
We studied 104 DIAs from 100 patients. The cases were 
selected retrospectively from the records of the 
Histopathology Department of Hospital Universitario Vall 
d’Hebron between 2000 and 2007 and classified histologi-
cally following the 2007 World Health Organization 
Classification of brain tumors. The 104 DIAs comprised 
19 (18%) grade II diffuse astrocytomas, 25 (24%) ana-
plastic astrocytomas, and 60 (57%) glioblastomas. The 
diagnosis was based on optical microscopy study of hema-
toxylin–eosin- stained slices and immunohistochemistry of 
GFAP, p53, and Ki67. A representative block per case 
was selected for the study of signaling pathway markers. 
Most of the selected GBM cases were large specimens 
because one of our main goals was to study expression 
throughout the tumor.
We used 15 cases of reactive astrocytosis to evaluate 
non- neoplastic activation of the cell proliferation pathways, 
mainly brain tissue around vascular lesions (nine cases 
of gliosis surrounding an arteriovenous malformation) and 
metastatic brain lesions (two cases of metastasis of breast 
carcinoma and four of lung adenocarcinoma).
Clinical and radiological data (age, sex, tumor site, type 
of surgical resection) were collected retrospectively from 
the clinical charts. Survival data were collected using the 
National Death Index between January and February 2012. 
Minimum follow- up was therefore 48 months.
Reagents and immunohistochemical analysis
A single representative block was selected for each case. 
Some included brain cortex. The tissue had previously been 
fixed in 10% buffered formalin and embedded in paraffin 
blocks. Three- micrometer thick slices were taken. The 
antibodies used and their dilutions are shown in Table 1.
Procedures
Immunohistochemistry was performed using the 
Benchmark XT platform with the ultraView Universal 
DAB Detection kit (Ventana Medical Systems, Tucson, 
Arizona) according to previously published protocols [6, 
7, 11]. Staining of EGFR was performed using the 
Autostainer Plus (Dako, Tucson, Arizona).
Immunohistochemistry evaluation
A histoscore (Hscore) was used to perform a semiquan-
titative evaluation of the antibodies EGFR, pMAPK, p4E-
 BP1, 4E- BP1, pS6, peIF4E, and eIF4E, as previously 
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described [5, 7, 10]. The Hscore was calculated by mul-
tiplying the intensity score by the percentage of stained 
cells (from 0% to 100%). The intensity score was ranged 
from 0 to 3, as follows: 0, no staining, 1, mildly intense 
staining; 2, moderate intense staining; and 3, strongly 
intense staining. Levels of Ki67, p53, and cyclin D1 were 
evaluated as the percentage of cells stained (nuclear stain-
ing). The presence or absence of the R132H mutation in 
IDH1 was evaluated using immunohistochemistry or PCR 
[11]. Neuronal staining and endothelial staining were used 
as positive internal controls.
Statistical analysis
The statistical analysis was performed using IBM SPSS 
Statistics for Windows, Version 20.0 (IBM Corp, Armonk, 
New York). Statistical significance was set at P < 0.05. The 
quantitative variables were age, histologic grade, proliferative 
activity (Ki67), cyclin D1, p53, and the Hscore of the pro-
teins studied. The qualitative variables were sex, location, 
laterality, and the presence of the IDH1 mutation.
Qualitative variables were compared using the chi- square 
test. Normally distributed quantitative variables were com-
pared using the t test and Pearson correlation; non- normally 
distributed quantitative variables were compared using 
Spearman’s rho and the Mann–Whitney test.
Receiver operating characteristic (ROC) curves were 
used to calculate the cut- offs that were most sensitive 
and specific for the diagnosis of high- grade versus low- 
grade disease or GBM versus other tumors in each of 
the markers. Once the cut- off was identified, the associa-
tion with survival was explored using Kaplan–Meier curves. 
The log- rank test was used to compare overall differences 
between the curves. Logistic regression models were con-
structed to identify which parameters were independently 
associated with high- grade disease or GBM.
The multivariate analysis was performed using Cox 
regression with the aim of finding the independent 
prognostic value for each of the variables analyzed. The 
diagnostic impact of the proteins was studied by creating 
a variable of high- grade DIA versus low- grade DIA and 
a variable of GBM versus non- GBM.
Results
Demographic and clinicopathological 
characteristics
Clinicopathological data are summarized in Table 2. The 
differences in age by group were statistically significant 
(P < 0.001). Mortality was 63.1% for grade II lesions, 
56% for grade III lesions, and 83.7% for GBM. Mean 
survival time was 1007 days (1567 for grade II, 1302 for 
grade III, and 520 for GBM). Significant differences in 
survival were found according to histological grade 
(P < 0.001) and age (P < 0001).
p4E- BP1
p4E- BP1 was expressed in the cytoplasm of tumor cells. 
A significant correlation was found between expression 
of p4E- BP1 and tumor grade (P < 0.001, Fig. 1F, G, H, 
and J). As for the impact of evaluating expression of 
p4E- BP1 on diagnosis, we found cut- off points revealing 
significant differences between groups, with high sensitivity 
(72.9%) that enabled us to differentiate GBM from astro-
cytomas of other grades. No significant differences in 
survival were found between groups with higher or lower 
p4E- BP1 levels.
4E- BP1
Expression of total 4E- BP1 in the cytoplasm of neoplastic 
cells increased with tumor grade (P < 0.001, Fig. 1B, C, 
D, and I). As for the impact of evaluating expression of 
4E- BP1 on diagnosis, we found cut- off points that 
Table 1. Information on the primary antibodies used in this study.
Antibody Phosphorylation site Supplier Host Dilution
EGFR Clone 2- 18C9 Dako Mouse Prediluted
PTEN Clone 6 h 2.1 Cascade ABM 2052 Mouse 1:300
pMAPK Cell Signaling Technology Rabbit 1:200
4E- BP1 Ser112 Cell Signaling Technology Rabbit 1:50
p4E- BP1 Thr70 Cell Signaling Technology Rabbit 1:50
pS6 Cell Signaling Technology Rabbit 1:100
eIF4E Ser209 Cell Signaling Technology Rabbit 1:75
peIF4E Clone EP2151Y Abcam Rabbit 1:200
Cyclin D1 Clone SP4 Ventana Rabbit Prediluted
Ki67 MIB1 Dako Mouse 1:100
IDH1 R132H Clone H09 Master Diagnostica Prediluted
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indicated significant differences between groups, with bet-
ter sensitivity for differentiation between high- grade and 
low- grade astrocytomas (70.5%) than in the diagnosis of 
GBM (60.3%) and a high positive predictive value (PPV, 
94.8%). No significant differences in survival were found 
between groups with higher or lower 4E- BP1 levels.
peIF4E
Phosphorylated eIF4E was expressed in the cytoplasm of 
tumor cells. Significant differences were found in expres-
sion of peIF4E for the different tumor grades (P < 0.001, 
Fig. 2F, G, H, and J). With respect to diagnosis, the 
cut- off points indicated significant differences between the 
groups, with better sensitivity in the diagnosis of GBM 
(94.3%) than in differentiation between high- grade and 
low- grade astrocytomas (81.4%), and a high PPV in both 
cases (96.6% in high grade vs. low grade and 87.7% in 
GBM vs. other grades). Phosphorylated eIF4E also had a 
significant impact on survival (Fig. 3A), even when the 
groups were stratified by grade. Multivariate analysis using 
Cox regression showed that peIF4E was the only inde-
pendent predictor of survival.
eIF4E
Cytoplasmic expression of eIF4E showed a statistically 
significant association with tumor grade (P < 0.001, Fig. 2B, 
C, D, and I). As for the diagnostic value of the eIF4E 
Hscore, we found the same cut- off with better sensitivity 
and specificity for the diagnosis of high- grade DIA than 
for the diagnosis of low- grade DIA, and for the diagnosis 
of GBM than for the diagnosis of DIA of other grades. 
In the first case, the PPV of eIF4E levels reached 100%.
Expression of eIF4E can also predict prognosis, with 
significant differences in survival between patients who 
exceed the cut- off (mean survival: 814 days) compared 
with those who do not (mean survival: 1911 days; 
P = 0.006, Fig. 3B). This finding holds for the whole 
population, but the differences are lost when patients are 
stratified by grade.
EGFR
EGFR was expressed in cell membranes, and the Hscore 
increased significantly with grade (P = 0.015). We found 
the same cut- off for separating low- grade and high- grade 
DIA (PPV, 93.8%) and for diagnosing GBM compared 
with other types of DIA (PPV, 81.3%). EGFR levels also 
had an impact on survival: patients with EGFR levels 
higher than 200 lived for 616 days, whereas those with 
lower levels lived for 1579 days (P = 0.005, Fig. 3C).
pS6
pS6 was expressed mainly in the cytoplasm. With respect 
to the role of pS6 in the diagnosis of DIA, after finding 
the cut- off with the greatest sensitivity for separating high- 
grade and low- grade DIA and for separating GBM from 
the remaining types of DIA, we observed that the differences 
between the groups were not real (P = 0.163 and 0.076). 
Similarly, pS6 had no impact on survival in our series.
Table 2. Clinicopathological data.
Characteristics Total neoplastic cases (%) Grade II Grade III Grade IV Gliosis
Total cases 104 (100) 19 (19) 25 (24) 60 (57) 15
Median age (years) 53 ± 15.7 43.53 ± 17.9 43.1 ± 14.3 60.3 ± 11.2 46.3
Gender
Male 37 (37.4) 12 (60) 21 (84%) 33 (55%) 10
Female 61 (62.6) 7 (40) 4 (16%) 27 (45%) 5
Location
Frontal lobe 35 (33.7) 8 9 18 NA
Temporal lobe 30 (28.8) 6 4 20 NA
Parietal lobe 8 (7.7) 2 2 4 NA
Occipital lobe 3 (2.9) 0 0 3 NA
Other location 13 (12.5) 2 5 6 NA
Location NA 15 (14.4) 1 5 9 NA
Surgical procedure
Lobectomy 34 (32.7) 7 10 17 NA
Subtotal resection 37 (35.6) 6 2 29 NA
Open biopsy 23 (22.1) 2 7 14 NA
Stereotactic biopsy 10 (9.6) 4 6 0 NA
OS (days) 1007 1567.8 1302.2 520.5 NA
NA, not applicable/not available; OS, overall survival.
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Figure 1. Expression of 4E- BP1 (A–D) and p4E- BP1 (E–H) in gliosis (A, E), diffuse astrocytoma (B, F), anaplastic astrocytoma (C, G), and glioblastoma 
multiforme (GBM) (D, H). Significant differences were found in 4E- BP1 (I) and 4E- BP1 (J) expression between grades, P < 0.001.
Histological grade Histological grade 
A 
G F E 
D C B 
H 
I J 
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Figure 2. Expression of peIF4E (A–D) and eIF4E (E–H) in gliosis (A, E), diffuse astrocytoma (B, F), anaplastic astrocytoma (C, G), and glioblastoma 
multiforme (GBM) (D, H). Significant differences (P < 0.001) were found in the expression of eIF4E (I) and peIF4E (J).
Histological grade Histological grade 
I J 
A D C B 
G F E H 
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pMAPK
Staining was positive in the cytoplasm and nucleus of tumor 
cells. No correlation was found between pMAPK expression 
and histological grade (Fig. 4A–F). No impact on diagnosis 
or on survival was found for pMAPK levels.
Cyclin D1
Cyclin D1 was expressed in the nucleus of tumor cells. 
The degree of expression was greater in the DIA group 
(P = 0.004), the GBM group (P < 0.001), and the ana-
plastic astrocytoma group (P = 0.039) than in the gliosis 
group. Significant differences were found between expres-
sion of cyclin D1 in diffuse astrocytoma and in high- grade 
DIA (P = 0.001).
As for the impact of cyclin D1 on diagnosis, the cut- 
off found was the same (statistically significant), with 
better sensitivity and specificity in the diagnosis of high- 
grade DIA compared with low- grade DIA and in the 
diagnosis of GBM compared with other DIAs. However, 
no statistically significant differences in survival were found 
between the groups based on these cut- offs.
Ki67
The tumor proliferation index increased with tumor 
grade (P < 0.001). The cut- off we found for Ki67 ena-
bled us to differentiate between high- grade and low- 
grade DIA and between GBM and other grades, with 
good PPV and sensitivity. In addition, significant dif-
ferences in survival were found between patients with 
Ki67 above the cut- off (mean: 942 days) and patients 
with a lower proliferative index (mean: 1936 days, 
P = 0.014, Fig 3D).
Figure 3. Significant differences in survival based on peIF4E score (A, P < 0.001), eIF4E score (B, P = 0.006), epidermal growth factor receptor (EGFR) 
score (C, P = 0.005), and Ki67 (D, P = 0.014).
peIF4E Hscore
<30 
>30 
<30, censored 
>30, censored 
EGFR Hscore
<200 
>200 
<200, censored 
>200, censored 
Ki67 (%) 
≤12% 
>12% 
≤12%, censored 
>12%, censored 
eIF4E Hscore
<40 
>40 
<40, censored 
>40, censored 
A B 
C D 
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Summary and combined evaluation of 
various proteins (nomograms)
Hscore values are summarized in Table 3 (median and 
confidence interval). As shown in Figure 5, central fac-
tors that control protein translation are overexpressed 
in high- grade gliomas. We applied a logistic regression 
model to analyze which variables were independently 
associated with a diagnosis of high- grade DIA or a 
diagnosis of GBM. The cut- off points that gave the 
best combinations were as follows: (1) 4E- BP1 >85 and 
peIF4E >30: diagnosis of GBM with a PPV of 100% 
(P < 0.001). (2) Cyclin D1 > 2% and peIF4E >30: 
diagnosis of high- grade DIA with a PPV of 98.7% 
(P < 0.001). (3) peIF4E <30 and Ki67 < 12%: exclu-
sion of GBM, with a negative predictive value of 100% 
(P < 0.001).
Secondary glioblastomas
No significant differences were found in levels of protein 
expression in the signaling pathways in the two cases of 
confirmed secondary GBM with respect to the remaining 
cases of GBM in the series (see Data S1).
Expression of cell signaling factors in gliosis
As a rule, the expression of most of the proteins studied 
was mild. Levels of p4E- BP1 (Fig. 1E), 4E- BP1 (Fig. 1A), 
peIF4E (Fig. 2E), eIF4E (Fig. 2A), and cyclin D1 and the 
Ki67 proliferative index were significantly lower in gliosis 
than in neoplasm in the whole group (P = 0.004 for 
cyclin D1, P < 0.001 for the other proteins). These dif-
ferences held for all three grades in p4E- BP1 and Ki67. 
As for 4E- BP1, eIF4E, and cyclin D1, expression in gliosis 
Figure 4. Expression of pMAPK in gliosis (A), diffuse astrocytoma (B), anaplastic astrocytoma (C), and glioblastoma multiforme (GBM) (D). No 
significant differences between grades were found in nuclear (E) and cytoplasmic (F) pMAPK expression.
E F 
Histological grade Histological grade 
B A C D 
2509© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
peIF4E: Prognostic Role in AstrocytomasE. Martínez- Sáez et al.
was significantly lower than in high- grade DIA but not 
grade II astrocytoma. Expression of peIF4E in gliosis was 
similar to that found in anaplastic astrocytoma and higher 
than that observed in grade II astrocytomas.
Cytoplasmic expression of pMAPK in gliosis was sig-
nificantly more pronounced than in GBM (P = 0.003), 
although no differences were found between gliosis and 
grade II and grade III astrocytoma. No differences were 
found regarding nuclear expression of pMAPK. pS6 levels 
in gliosis were similar to those detected in tumors, with 
no significant differences between the tumor group and 
the nontumor group.
Discussion
Cell signaling coordinates basic cellular activities and is 
based on growth factor membrane receptors and intracel-
lular signaling pathways such as RAS- Raf- MAPK, STAT3, 
and PI3K- AKT- mTOR. We showed that the levels of these 
factors (p4E- BP1, peIF4E) increase during tumor progres-
sion and that peIF4E, age, and histologic grade were 
independent prognostic factors in the multivariate analysis. 
These results are consistent with those of previous studies 
in several types of carcinomas, where p4E- BP1, eIF4E, 
and peIF4E were overexpressed, associated with a poorer 
Table 3. Hscore (median values and confidence interval) for p4E- BP1, 4E- BP1, peIF4E, eIF4E, EGFR, pS6, and pMAPK in gliosis cases, grade II diffuse 
astrocytomas, AA, and GBM. Cyclin D1 and Ki67 are expressed as percentages.
Gliosis DA AA GBM
Median CI [5–95%] Median CI [5–95%]Median CI [5–95%] Median CI [5–95%]
p4E- BP1 5 0–20 80 0–185 120 20–220 165 30–275
4E- BP1 20 5–50 40 5–130 70 5–170 100 10–200
peIF4E 30 10–90 5 0–110 10 0–130 100 30–190
eIF4E 5 5–60 5 5–40 30 5–160 75 5–185
EGFR - 1 - 1 140 0–225 140 0–300 225 15–300
pS6 120 30–170 65 5–230 40 5–230 90 20–240
pMAPK2 150 0–188 35 0–185 80 0–215 55 0–200
Cyclin D1 5 0–30 5 0–20 15 0–50 15 0–40
Ki67 1 0–3 5 1–15 15 2–45 25 5–75
DA, diffuse astrocytoma; AA, anaplastic astrocytoma; GMB, glioblastoma multiforme; CI, confidence interval. EGFR, epidermal growth factor 
receptor.
1The EGFR study was not performed in cases of gliosis.
2pMAPK values correspond to cytoplasmic pMAPK.
Figure 5. Differences in the expression of the different studied proteins in grade II astrocytomas and GBM (mean levels).
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prognosis, and considered critical “funnel factors” in cell 
signaling [3, 5–8, 12–14].
The protein 4E- BP1 and its phosphorylated form have 
received little attention in the context of DIAs [15–17]. 
In the present study, we found a correlation between 
tumor grade and levels of expression of the total and 
phosphorylated forms of 4E- BP1. Similar results were 
previously reported in a study on p4E- BP1 by 
Korkolopoulou et al. [15], who examined a series of 
111 DIAs and found a correlation between expression 
of p4E- BP1 and tumor grade. Of the many factors involved 
in the mTOR pathway analyzed by this group, p4E- BP1 
was the only one that showed a correlation with MAPK. 
The authors reported that p4E- BP1 predicted a worse 
prognosis, regardless of the mutational status of IDH1. 
Even though we found that p4E- BP1 levels correlated 
with survival, p4E- BP1 was not an independent prog-
nostic factor in the present series. In addition, no asso-
ciation was found with the mutational status of IDH1, 
although it is important to remember that the number 
of GBMs with the R132H mutation in our series is 
insufficient to draw statistical comparisons. Ermoian et al.
[16] studied p4E- BP1 levels using immunoblotting in 
71 DIA specimens distributed homogeneously into three 
groups according to tumor grade (28 grade II, 17 ana-
plastic astrocytoma, and 26 GBM), with a control group 
of 16 non- neoplastic specimens. The results reported 
were similar to ours when the four groups were com-
pared (statistically significant correlation between levels 
of p4E- BP1 and progression of tumor grade); however, 
statistical significance disappeared when the control group 
was removed. Differences were found in the expression 
of pAKT between the group formed by control cases 
and low- grade tumors and the group comprising high- 
grade tumors. As for the mTOR complex, the authors 
found reduced levels of the mTOR- suppressing proteins 
hamartin and tuberin (TSC1 and TSC2) as the tumor 
grade increased. This halt in the inhibition of mTOR 
enables it to act on 4E- BP1 by phosphorylating it and 
thus increasing p4E- BP1 levels. An association was found 
between the increase in pAKT and p4E- BP1, but not 
between pAKT and S6. Similarly, no impact on survival 
was recorded. In their study of 29 cases of GBM, 
Riemenschneider et al. [17] reported that activation of 
AKT did not imply a statistically significant increase in 
p4E- BP1 levels. These findings support the possibility 
that kinases other than mTOR (like CDK1) could phos-
phorylate 4E- BP1 [6, 18].
Overexpression of eIF4E has been reported in cancer 
of the lung, breast, prostate, bladder, cervix, ovary, thyroid, 
and head and neck, as well as in hematologic neoplasms 
[19]. It is associated with tumor progression and poor 
prognosis in cancer of the breast [20], bladder [21, 22], 
prostate [23, 24], and cervix [25], and in lung adenocar-
cinoma [26, 27]. Consistent with reports on these tumors, 
we observed overexpression of eIF4E in astrocytoma with 
respect to gliosis. Only one study has compared overex-
pression of eIF4E in high- grade astrocytoma (10 cases of 
anaplastic astrocytoma and GBM) and non- neoplastic brain 
parenchyma [28]. The statistically significant correlation 
between more marked expression of eIF4E with higher 
tumor grade and poor prognosis in DIA had not been 
previously reported. In other tumors, expression of eIF4E 
was reported to be more marked in neoplastic lesions 
than in preneoplastic lesions (e.g., higher expression of 
eIF4E in adenocarcinoma than in adenomatous polyps in 
the colon [26] or in infiltrating carcinoma compared with 
benign tumors of the head and neck [29]).
The biological significance of phosphorylation of eIF4E 
and its effect on translation is not well understood. Some 
studies indicate that phosphorylation of eIF4E reduces 
the affinity of this protein for the 5′ end of the mRNA 
strand [30]. This phosphorylation does not seem to play 
an important role in the normal functioning of the 
healthy cell, although it does appear to play a key role 
in tumors and has been associated with increased syn-
thesis of several proteins involved in the development 
of neoplasms (McI- 1, MMP- 3, and cyclin D1) [24]. 
Similarly, peIF4E has been shown to confer resistance 
in situations of cellular stress, such as starving and 
genomic damage [31].
Phosphorylation of eIF4E increases in the initial stages 
of the development of tumors of the breast, colon, 
stomach, and lung. It increases in prostate cancer and 
is associated with neoplastic growth not related to andro-
gens [32], although differences in peIF4E expression have 
not been reported between tumors with and without 
nodal metastasis [33]. Fan et al. report overexpression 
of peIF4E using immunohistochemistry in a case of 
astrocytoma from a small series of five cases with no 
expression of the protein in healthy brain tissue. In the 
present study, we observed that the phosphorylated form 
of eIF4E increased with tumor grade. Marked expression 
of this protein was the only independent prognostic 
factor among those involved in the cell signaling path-
ways analyzed.
Diagnostic and therapeutic implications
Biopsy specimens for the diagnosis of DIA are often small, 
and the histologic characteristics of the material sent for 
analysis do not always coincide with the radiologic appear-
ance of the lesion. In such cases, molecular data such as 
amplification of EGFR can be useful in clinical decision 
making. We asked whether the proteins investigated in 
the present study had a predictive value in the diagnosis 
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of high- grade astrocytoma and GBM and an impact on 
survival. Thus, even if histologic criteria are not fulfilled, 
a DIA lesion showing expression of 4E- BP1 and peIF4E 
with Hscores >85/300 and 30/300, respectively, could sug-
gest a diagnosis of GBM (with a positive predictive value 
of 100%, P < 0.001). In such cases, it would be necessary 
to evaluate the risk–benefit ratio of a new biopsy.
Phosphorylation of 4E- BP1 and eIF4E are examples of 
activation of multiple biochemical pathways upstream, 
where many oncogenic abnormalities may be activated. 
Phosphorylation of eIF4E was recently shown to confer 
greater aggressivity in cells and in the development of 
metastasis in murine models [34]. It is also associated 
with resistance to oxidative stress, nutrient deprivation, 
and cytotoxic stress [31, 34]. Therefore, inhibition of 
phosphorylation was proposed as a therapeutic target. In 
clinical terms, attempts have been made to inhibit expres-
sion of eIF4E with antisense oligonucleotides, which block 
binding to eIF4G and inhibit phosphorylation with MAPK 
inhibitors and with ribavirin [21, 32, 35]. MNK inhibitors 
such as CGP 57380 and cercosporamide block growth of 
GBM in animal models [36] and yield better results when 
combined with mTOR inhibitors. In vitro blockade of 
eIF4E by CGP 57380 is sufficient to reduce cell migration 
and cellular resistance to neoplastic cells and chemothera-
peutic agents [21, 31, 37]. Inhibiting phosphorylation of 
eIF4E by inhibition of MAPK and MNKs could then 
block the proliferative effect of eIF4E. It could therefore 
prove useful for sensitizing tumor cells to anticancer 
agents, thus highlighting the usefulness of combining eIF4E 
phosphorylation inhibitors with other antitumor agents 
[31].
Acknowledgments
We acknowledge support from the Fondo de Investigaciones 
Sanitarias (PI08/0143 and PI11/00185), Redes temáticas 
de Investigación Cooperativa en Salud (RTICC, 
RD12/0036/0057), Generalitat de Catalunya (AGAUR, 2009 
SGR 756), and Fundación Mutua Madrileña 
(FMMA/2009/02). The samples used in this project were 
provided by the Tumor Bank of the Vall d’Hebron 
University Hospital Biobank, with appropriate ethical 
approval (supported by the Xarxa de Bancs de Tumors 
de Catalunya [XBTC] and sponsored by Pla Director 
d’Oncología de Catalunya), supported by the Plataforma 
de Biobancos (ISCIII). E. M.- S. was supported by a Río 
Hortega grant, ISCIII (CM09/00143).
Conflict of Interest
None declared.
References
 1. Louis, D. N., H. Ohgaki, O. D. Wiestler, and W. K. 
Cavenee. 2007. WHO Classification of Tumours of the 
Central Nervous System, 4th ed. International Agency 
for Research on Cancer, Lyon.
 2. Ohgaki, H., and P. Kleihues. 2013. The definition of 
primary and secondary glioblastoma. Clin. Cancer Res. 
19:764–772.
 3. Armengol, G., F. Rojo, J. Castellví, et al. 2007. 4E- 
binding protein 1: a key molecular “funnel factor” in 
human cancer with clinical implications. Cancer Res. 
67:7551–7555.
 4. Ramon, Y., S. Cajal, L. De Mattos-Arruda, N. 
Sonenberg, J. Cortes, and V. Peg. 2014. The intra- tumor 
heterogeneity of cell signaling factors in breast cancer: 
p4E- BP1 and peIF4E are diffusely expressed and are real 
potential targets. Clin. Transl. Oncol. 16:937–941.
 5. Castellvi, J., A. Garcia, C. Ruiz-Marcellan, et al. 2009. 
Cell signaling in endometrial carcinoma: phosphorylated 
4E- binding protein- 1 expression in endometrial cancer 
correlates with aggressive tumors and prognosis. Hum. 
Pathol. 40:1418–1426.
 6. Pons, B., V. Peg, M. A. Vázquez-Sánchez, et al. 2011. 
The effect of p- 4E- BP1 and p- eIF4E on cell 
proliferation in a breast cancer model. Int. J. Oncol. 
39:1337–1345.
 7. Castellvi, J., A. Garcia, F. Rojo, et al. 2006. 
Phosphorylated 4E binding protein 1: a hallmark of cell 
signaling that correlates with survival in ovarian cancer. 
Cancer 107:1801–1811.
 8. Benavente, S., R. Vergés, E. Hermosilla, et al. 2009. 
Overexpression of phosphorylated 4E- BP1 predicts for 
tumor recurrence and reduced survival in cervical 
carcinoma treated with postoperative radiotherapy. Int. 
J. Radiat. Oncol. Biol. Phys. 75:1316–1322.
 9. Cedrés, S., M. A. Montero, P. Martinez, et al. 2012. 
Exploratory analysis of activation of PTEN- PI3K 
pathway and downstream proteins in malignant pleural 
mesothelioma (MPM). Lung Cancer 77:192–198.
10. Rojo, F., L. Najera, J. Lirola, et al. 2007. 4E- binding 
protein 1, a cell signaling hallmark in breast cancer that 
correlates with pathologic grade and prognosis. Clin. 
Cancer Res. 13:81–89.
11. Horbinski, C., J. Kofler, L. M. Kelly, G. H. Murdoch, 
and M. N. Nikiforova. 2009. Diagnostic use of IDH1/2 
mutation analysis in routine clinical testing of formalin- 
fixed, paraffin- embedded glioma tissues. J. Neuropathol. 
Exp. Neurol. 68:1319–1325.
12. Ferrandiz-Pulido, C., E. Masferrer, A. Toll, et al. 2013. 
mTOR signaling pathway in penile squamous cell 
carcinoma: pmTOR and peIF4E over expression 
correlate with aggressive tumor behavior. J. Urol. 
190:2288–2295.
2512 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
E. Martínez- Sáez et al.peIF4E: Prognostic Role in Astrocytomas
13. Roh, M. S., J. H. Lee, K. W. Kang, et al. 2015. 
Phosphorylated 4E- binding protein 1 expression is 
associated with poor prognosis in small- cell lung cancer. 
Virchows Arch. 467:667–673.
14. Yoshizawa, A., J. Fukuoka, S. Shimizu, et al. 2010. 
Overexpression of phospho- eIF4E is associated with 
survival through AKT pathway in non- small cell lung 
cancer. Clin. Cancer Res. 16:240–248.
15. Korkolopoulou, P., G. Levidou, E. A. El-Habr, et al. 
2012. Phosphorylated 4E- binding protein 1 (p- 4E- BP1): 
a novel prognostic marker in human astrocytomas. 
Histopathology 61:293–305.
16. Ermoian, R. P., T. Kaprealian, K. R. Lamborn, et al. 
2009. Signal transduction molecules in gliomas of all 
grades. J. Neurooncol. 91(1):19–26.
17. Riemenschneider, M. J., R. A. Betensky, S. M. Pasedag, 
and D. N. Louis. 2006. AKT activation in human 
glioblastomas enhances proliferation via TSC2 and S6 
kinase signaling. Cancer Res. 66:5618–5623.
18. Greenberg, V. L., and S. G. Zimmer. 2005. Paclitaxel 
induces the phosphorylation of the eukaryotic translation 
initiation factor 4E- binding protein 1 through a 
Cdk1- dependent mechanism. Oncogene 24:4851–4860.
19. Carroll, M., and K. L. Borden. 2013. The oncogene 
eIF4E: using biochemical insights to target cancer. J. 
Interferon Cytokine Res. 33:227–238.
20. De Benedetti, A., and J. R. Graff. 2004. eIF- 4E 
expression and its role in malignancies and metastases. 
Oncogene 23:3189–3199.
21. Pettersson, F., S. V. Del Rincon, and W. H. Miller. 
2014. Eukaryotic translation initiation factor 4E as a 
novel therapeutic target in hematological malignancies 
and beyond. Expert Opin. Ther. Targets 18:1035–1048.
22. Crew, J. P., S. Fuggle, R. Bicknell, D. W. Cranston, A. 
de Benedetti, and A. L. Harris. 2000. Eukaryotic 
initiation factor- 4E in superficial and muscle invasive 
bladder cancer and its correlation with vascular 
endothelial growth factor expression and tumour 
progression. Br. J. Cancer 82:161–166.
23. Graff, J. R., B. W. Konicek, R. L. Lynch, et al. 2009. 
eIF4E activation is commonly elevated in advanced 
human prostate cancers and significantly related to 
reduced patient survival. Cancer Res. 69:3866–3873.
24. Furic, L., L. Rong, O. Larsson, et al. 2010. eIF4E 
phosphorylation promotes tumorigenesis and is 
associated with prostate cancer progression. Proc. Natl 
Acad. Sci. USA 107:14134–14139.
25. Matthews-Greer, J., A. DeBenedetti, A. Tucker, S. 
Dempsey, D. Black, E. Turbat-Herrera. 2002. A model 
for angiogenesis in HPV-mediated cervical cancer. J. 
Appl. Res. 2:63–73.
26. Rosenwald, I. B., J. J. Chen, S. Wang, L. Savas, I. M. 
London, and J. Pullman. 1999. Upregulation of 
protein synthesis initiation factor eIF- 4E is an early 
event during colon carcinogenesis. Oncogene 
18:2507–2517.
27. Seki, N., T. Takasu, K. Mandai, et al. 2002. Expression 
of eukaryotic initiation factor 4E in atypical 
adenomatous hyperplasia and adenocarcinoma of the 
human peripheral lung. Clin. Cancer Res. 8:3046–3053.
28. Gu, X., L. Jones, M. Lowery-Norberg, and M. Fowler. 
2005. Expression of eukaryotic initiation factor 4E in 
astrocytic tumors. Appl. Immunohistochem. Mol. 
Morphol. 13:178–183.
29. Haydon, M. S., J. D. Googe, D. S. Sorrells, G. E. Ghali, 
and B. D. Li. 2000. Progression of eIF4e gene 
amplification and overexpression in benign and malignant 
tumors of the head and neck. Cancer 88:2803–2810.
30. Hou, J., F. Lam, C. Proud, and S. Wang. 2012. Targeting 
Mnks for cancer therapy. Oncotarget 3:118–131.
31. Martínez, A., M. Sesé, J. H. Losa, et al. 2015. 
Phosphorylation of eIF4E Confers Resistance to Cellular 
Stress and DNA- Damaging Agents through an 
Interaction with 4E- T: A Rationale for Novel 
Therapeutic Approaches. PLoS ONE 10:e0123352.
32. Bhat, M., N. Robichaud, L. Hulea, N. Sonenberg, J. 
Pelletier, and I. Topisirovic. 2015. Targeting the translation 
machinery in cancer. Nat. Rev. Drug Discov. 14:261–278.
33. Fan, S., S. S. Ramalingam, J. Kauh, Z. Xu, F. R. Khuri, 
and S. Y. Sun. 2009. Phosphorylated eukaryotic 
translation initiation factor 4 (eIF4E) is elevated in 
human cancer tissues. Cancer Biol. Ther. 8:1463–1469.
34. Robichaud, N., S. V. del Rincon, B. Huor, et al. 2015. 
Phosphorylation of eIF4E promotes EMT and metastasis 
via translational control of SNAIL and MMP- 3. 
Oncogene 34:2032–2042.
35. Assouline, S., B. Culjkovic, E. Cocolakis, et al. 2009. 
Molecular targeting of the oncogene eIF4E in acute 
myeloid leukemia (AML): a proof- of- principle clinical 
trial with ribavirin. Blood 114:257–260.
36. Grzmil, M., R. M. Huber, D. Hess, et al. 2014. MNK1 
pathway activity maintains protein synthesis in rapalog- 
treated gliomas. J. Clin. Invest. 124:742–754.
37. Pettersson, F., S. V. Del Rincon, A. Emond, et al. 2015. 
Genetic and pharmacologic inhibition of eIF4E reduces 
breast cancer cell migration, invasion, and metastasis. 
Cancer Res. 75:1102–1112.
Supporting Information
Additional supporting information may be found in the 
online version of this article:
Data S1. Secondary GBM.
